In search of 'house­hold health­care brands of the fu­ture,' Fore­site Cap­i­tal rais­es $969M to sa­ti­ate a tech-heavy ap­petite

Back in April 2018, just be­fore Fore­site Cap­i­tal un­veiled its $668 mil­lion Fund IV and a strat­e­gy to fo­cus on tech-dri­ven life sci­ence bets, one of its port­fo­lio com­pa­nies qui­et­ly made an an­nounce­ment.

Fount Ther­a­peu­tics, a drug dis­cov­ery out­fit backed by Fore­site and Es­hel­man Ven­tures, had raised $22 mil­lion in Se­ries A cash to hatch sev­er­al fledg­ling spin­outs. “The first ‘New­Co,’ Kin­nate, will be fo­cused on de­vel­op­ing pre­ci­sion on­col­o­gy treat­ments,” read a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER